FIELD: pharmaceuticals; medicine.
SUBSTANCE: invention concerns a method of non-surgical treatment of focal and cavitary changes in the lungs of post-Covid etiology. A course of 1 to 12 months of combined inhalation therapy with Triavir Ingal ®in combination with Atrovent mixed with Lazolvan is used. A single dose of Triavir Ingal® is 5 ml, of Atrovent is 2 ml, of Lazolvan is 2 ml, inhalations are performed 3 times a day. Additionally, control examinations are carried out 1, 3, 6 and/or 12 months after the start of treatment. The examination includes auscultation, measurement of saturation using a pulse oximeter, study of control computed tomography data and recording of all changes that occurred during the treatment, and assessment of the degree of shortness of breath is also performed. The effectiveness and safety of treatment, as well as the possibility of use in an outpatient setting.
EFFECT: invention ensures the effectiveness and safety of treatment, as well as the possibility of use in outpatient settings.
3 cl, 27 dwg, 1 tbl, 5 ex
